BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 25644425)

  • 1. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
    Straccia P; Rossi ED; Bizzarro T; Brunelli C; Cianfrini F; Damiani D; Fadda G
    Cancer Cytopathol; 2015 Dec; 123(12):713-22. PubMed ID: 26355876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic potential of ancillary molecular testing in differentiation of benign and malignant thyroid nodules.
    Bhatia P; Deniwar A; Friedlander P; Aslam R; Kandil E
    Anticancer Res; 2015 Mar; 35(3):1237-41. PubMed ID: 25750270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclassification of follicular neoplasms recommended by the Japan thyroid association reporting system of thyroid cytology.
    Kakudo K; Kameyama K; Hirokawa M; Katoh R; Nakamura H
    Int J Endocrinol; 2015; 2015():938305. PubMed ID: 25722720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid cytopathology reporting by the bethesda system: a two-year prospective study in an academic institution.
    Mehra P; Verma AK
    Patholog Res Int; 2015; 2015():240505. PubMed ID: 25688327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of Thyroid FNAC as a Single Diagnostic Modality: A Systematic Review.
    Poduval J; Bhat V; Naik P
    Indian J Otolaryngol Head Neck Surg; 2019 Oct; 71(Suppl 1):167-171. PubMed ID: 31741954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.
    Koh J; Moon HJ; Kim EK; Kwak JY; Yoon JH
    Endocrine; 2016 Aug; 53(2):489-96. PubMed ID: 26758996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid cytopathology: updates and molecular testing.
    Vance J; Gilani SM
    Pathologica; 2019 Jun; 111(2):51-57. PubMed ID: 31388195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
    Wong LQ; Baloch ZW
    Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories.
    Onder S; Firat P; Ates D
    Cytopathology; 2014 Jun; 25(3):177-84. PubMed ID: 23998291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.
    Bongiovanni M; Giovanella L; Romanelli F; Trimboli P
    Thyroid; 2019 Feb; 29(2):222-228. PubMed ID: 30426887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Bethesda reporting category, 'suspicious for papillary thyroid carcinoma', pitfalls and clues to optimize the use of this category.
    Mahajan A; Lin X; Nayar R
    Cytopathology; 2013 Apr; 24(2):85-91. PubMed ID: 22356185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
    Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
    Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing indeterminate thyroid FNAs.
    Renshaw AA; Gould EW
    Cancer Cytopathol; 2015 Apr; 123(4):237-43. PubMed ID: 25644425
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.